Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy

Abstract

Described herein are various lipid mixtures, more particularly special mixtures of fatty acids esters, which may be phytosterol esters and / or glyceride esters. Said mixtures are evaluated in the context of their ability to, upon consumption, affect the levels of circulating LDL and HDL particles, and their therapeutic effect on conditions associated with lipid metabolism, such as atherosclerosis, diabetes, metabolic disorders, etc. Compositions, dietary nutrients, food supplements and nutraceuticals comprising the herein described mixtures are also described.

Description

CROSS REFERENCE TO RELATED APPLICATION [0001] This application is a Continuation in Part of U.S. patent application Ser. No. 11 / 199,584 filed Aug. 8, 2005, which is a Continuation in Part of International Patent Application No. PCT / IL2004 / 000131 filed Feb. 10, 2004.FIELD OF THE INVENTION [0002] The present invention relates to various lipid mixtures, more particularly special mixtures of fatty acids esters, which may be phytosterol esters and / or glyceride esters, as well as compositions, dietary nutrients, food supplements and nutraceuticals comprising thereof, intended for the treatment and prevention of diseases and conditions associated with lipid metabolism. BACKGROUND OF THE INVENTION [0003] All publications mentioned throughout this application are fully incorporated herein by reference, including all references cited therein. [0004] Coronary Artery Disease (like atherosclerosis) is the major cause of morbidity and mortality in the Western world and its pathogenesis involves c...

AI Technical Summary

Benefits of technology

[0036] The mixture described herein, or the edible composition of matter comprising thereof, is intended for various uses, including: (a) reducing the risk of developing metabolic disorder and / or insulin resistance syndrome; (b) reducing circulating atherogenic small-dense LDL particles, while maintaining a high proportion of HDL / LDL ratio; (c) shifting the HDL profile in the direction of larger and less dense particles, particularly reducing the HDL3 sub-fraction while increasing the level of HDL2 sub-fraction; (d) reducing and / or preventing the progression of the metabolic disorder and / or insulin resistance syndrome and / or atherosclerotic deleterious processes;

[0040] Similarly, said pharmaceutical dosage form is intended for the same uses as described above for the mixture of the invention, i.e., in reducing the risk of developing metabolic disorder and / or insulin resistance syndrome; in reducing circulating atherogenic small-dense LDL particles, while maintaining a high proportion of HDL / LDL ratio; in shifting HDL profile in the direction of larger and less dense particles, particularly reducing the HDL3 subfraction while increasing the level of HDL2 subfraction; in reducing and / or preventing the progression of the metabolic disorder and / or insulin resistance syndrome and / or atherosclerotic deleterious processes; in attenuating or counteracting any adverse effects of use of omega-3 fatty acids in the form of oils, wherein said adverse effect may be elevating LDL cholesterol or increasing the total / HDL cholesterol ration, related to a decrease in HDL cholesterol levels.

Problems solved by technology

Similarly, it is well known that low levels of HDL cholesterol (HDL-C) are associated with an increased risk for CVD independent of LDL-C levels, and that raising HDL-C has been shown to significantly lower CVD risk.

However, none of the above mentioned publications describes reduction of both cholesterol and triglycerides serum levels.

Images